Structural Biology & Lead Discovery Services

Premium Structural Biology & Lead Discrovery Services

SARomics Biostructures provides premium structural biology and structure-based drug discovery services to the biotech industry and academic institutions. We have many years of experience and proven excellence in protein production, biophysical characterization and crystallization, protein X-ray crystallography and BioNMR spectroscopy, fragment screening, and fragment-based lead generation.

Please visit the "about" pages for additional company information. For details on the experimental methods, visit our technology platform overview. You may also view a blog post on how structural biology may help drug discovery.

For the details of our services, follow the links below. You may also contact us directly for a company presentation and project discussion.
Search the site, e.g., for a protein of interest:
For the latest blog posts, click here.

X-ray Crystallography and Protein NMR Services

X-ray crystallography

gene-to-structure services, X-ray crystallography services
Our protein X-ray crystallography services provide protein crystallization and X-ray structure determination, FastLane™ Premium and FastLane™ standard libraries of verified drug targets (off-the-shelf structures), protein production and custom gene-to-structure and protein-ligand complex X-ray structure determination.

Protein NMR spectroscopy

protein NMR spectroscopy services, fragment screening and ligand binding
We provide a broad range of custom protein NMR (BioNMR) spectroscopy services that include peptide, protein, protein-ligand & protein-protein complex NMR assignment and 3D structure determination, NMR fragment screening using 1D or 2D NMR, epitope mapping and dissociation constant (Kd) determinations for compounds.

Antibodies & biosimilars

antibody and antibody-antigen complex strucure charaterization, high order structure of biosimilars
Antibody and antibody-antigen complex crystallization and high resolution X-ray structure determination, BioNMR and crystallographic characterization of higher order structure (HOS) of biosimilars, comparison with originator antibody and formulation optimization, biophysical characterization of antibodies and biosimilars in solution.

Fragment screening & structure-based lead discovery

Fragment library screening

weak-affinity chromatography, fragment-based drug design
High throughput (2000-3000 cmpds/week), robust and accurate (validated against NMR and X-ray) fragment screening using weak-affinity chromatography (WAC™), which also includes binding assay and measurement of fragment affinity to immobilized protein - all in one experiment!

Computational chemistry

computational chemistry services, in silico screening and drug design
Computation chemistry is an integral part of our structure-based lead discovery services. We use state-of-the-art computational chemistry software and have gathered extensive experience in all aspects of computational chemistry, including:
  • Virtual screening services
  • Pharmacophore and shape-based virtual screening
  • Ligand-based drug design, etc.

Integrated lead discovery

integrated drug discovery services
Our integrated lead discovery and structure-based drug design (SBDD) services include fragment screening, hit identification, hit-to-lead, and lead optimization. In collaboration with our in-house partner, Read Glead Discovery, we offer structure-based hit expansion, hit-to-lead, and lead optimization services.

State-of-the-art structural biology technology platform

Our technology services platform is equipped with state-of-the-art instrumentation for all aspects of structural biology, including protein production, robotic nanoliter-scale crystallization screening and optimization of conditions for crystal growth, and crystallization drop imaging. For X-ray crystallographic data collection, we use the MAX IV synchrotron radiation facility (image above), located a couple of kilometers from our labs in Lund. Alternatively, we send the crystals to other European synchrotrons. We collect X-ray data approximately every second week.

We have access to high-quality, cutting-edge instrumentation for NMR spectroscopy services. We provide de novo NMR protein structure determination, protein-ligand/protein-protein complex NMR structure determination, small molecule fragment library screening, and much more…

You may use the form below to contact us if you have questions about our structural biology services platform.
Maria Håkansson and Raymond Kimbung, protein crystallization facility at SARomics Biostructures

News updates and blog posts

Our blog provides the latest company updates, an overview of the latest publications, and general posts discussing various aspects of structural biology, structure-based lead discovery, and drug design. Older news can be found in our news archive, and a list of recent publications on our publications page.

Monoclonal therapeutics antibodies

The development of new drugs of biological origin (biologics), the majority of which are monoclonal antibodies, is a significant focus of modern-day drug discovery and design. In this post, we discuss the role of the three-dimensional structure in antibody engineering and the development of monoclonal antibody therapeutics.
Read more…

Biosimilars & comparability analysis

The second part of our article series on antibody therapeutics discusses the field of biosimilar therapeutics - monoclonal biosimilars, and the need for higher order structure (HOS) comparability analysis before they get approved by regulating agencies.
Read more…

Biosimilars: NMR in assessing comparability

The third article in our series about therapeutic monoclonal antibodies focuses on structural characterization and comparability analysis of biosimilars. We discuss existing evidence that shows that NMR spectroscopy is far superior to other established methods for comparability assessment.
Read more…